[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal-diseases-and-abnormalities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal-diseases-and-abnormalities":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100605719","prospective-registry-for-long-term-outcomes-following-feto-in-severe-left-and-right-cdh-100605719",false,"NCT07166172","Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH","North American Fetal Therapy Network Prospective Registry for Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia","Inclusion Criteria:\n\n* Pregnant women age 18 years and older\n* Singleton pregnancy\n* Normal Karyotype, chromosomal microanalysis (CMA) with non-pathologic variants, whole exome sequencing (WES) or whole genome sequencing (WGS). Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is \\> 26 weeks gestation.\n* Gestational age at enrollment is prior to 29 weeks + 6 days gestation.\n* Intrathoracic liver herniation:\n\n  * Isolated left CDH with o\u002Fe LHR \\\u003C 30% at enrollment (18wks + 0 days to 29wks + 5 days gestation).\n  * Isolated right CDH with o\u002Fe LHR ≤ 45% at enrollment (18wks + 0 days to 29wks + 5 days gestation).\n* Cervical length by transvaginal ultrasound ≥ 20 mm within 24 hours prior to FETO procedure.\n* Patient meets psychosocial criteria.\n* Informed consent understood.\n\nExclusion Criteria:\n\n* Patient \\\u003C 18 years of age\n* Multi-fetal pregnancy\n* History of natural rubber latex allergy\n* Preterm labor, cervix shortened (\\\u003C20 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa.\n* Psychosocial ineligibility, precluding consent:\n\n  1. Inability to reside within 30 minutes of Johns Hopkins Hospital Center for Fetal Therapy.\n  2. The patient does not have a support person (e.g., spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Johns Hopkins Hospital Center for Fetal Therapy.\n* Bilateral CDH, isolated left sided CDH with O\u002FE LHR ≥ 30% (18wks + 0 days to 29wks + 5 days gestation), isolated right sided CDH with O\u002FE LHR \\> 45% (18wks + 0 days to 29wks + 5 days gestation), as determined by ultrasound.\n* No liver herniation into thoracic cavity.\n* Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram at the fetal treatment center. Exclude chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., CDH and congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns).\n* Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy.\n* History of incompetent cervix with or without cerclage.\n* Placental abnormalities (previa, abruption, accreta) known at time of enrollment\n* Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy.\n* Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment.\n* Uterine anomalies such as large or multiple fibroids or Mullerian duct abnormality.\n* There is no safe or technically feasible fetoscopic approach to balloon placement.\n* Participation in another intervention study that influences maternal and fetal morbidity and mortality. or participation in this trial in a previous pregnancy.","FEMALE","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","This registry study aims to confirm that FETO increases neonatal survival to discharge and reduces long-term morbidity in fetuses with isolated left CDH and o\u002Fe LHR \\\u003C 30%, or isolated right CDH and o\u002Fe LHR ≤ 45%, compared to those receiving standard care. This prospective registry plans to enroll 80 pregnant women (40 treatment\u002F40 control) with fetuses diagnosed with isolated CDH, and the children will be followed for up to 24 months.",[26,27,28,29,30,31,32,33],"Congenital Diaphragmatic Hernia","Congenital Abnormalities","Neonatal Diseases and Abnormalities","Hernia, DIaphragmatic, Congenital","Internal Hernia","Hernia","Pathological Conditions, Anatomical","Pathological Conditions, Signs and Symptoms",[35],"Fetoscopic Endoluminal Tracheal Occlusion","RECRUITING","2026-04-20",{"date":39,"type":40},"2026-04-23","ACTUAL",{"date":42,"type":40},"2025-06-23",{"date":44,"type":20},"2031-12-01",{"name":46,"class":47},"Johns Hopkins University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100607046","phase-4-azithromycin-and-ampicillin-for-late-pprom-100607046","NCT07183462","Azithromycin and Ampicillin for Late PPROM","ALPRO","Inclusion Criteria:\n\n* Maternal age 18-50\n* Premature rupture of membranes\n* Gestational age 34.0 and 36.4 weeks\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Multiple gestations\n* Individuals in active labor (defined as 3 cm dilatation and 80% effacement or more. or regular uterine construction of more than 4 in 10 minutes)\n* Meconium stain amniotic fluid\n* Non-reassuring fetal heart rate or status\n* Maternal or fetal indication for labor:\n\n  * Suspected Chorioamnionitis\n  * Suspected placental abruption\n  * Any maternal morbidity requiring labor\n* Cervical cerclage in place.\n* Major fetal malformation or known chromosomal abnormalities.\n* Stillbirth.\n* Sensitivity to Macrolides Antibiotics","50 Years",{"count":58,"type":20},311,[60],"PHASE4","The goal of this clinical trial is to learn whether adding azithromycin to the standard antibiotic treatment (ampicillin) improves newborn outcomes in women with preterm premature rupture of membranes (PPROM) between 34.0 and 36.6 weeks of pregnancy.\n\nThe main question it aims to answer is:\n\nDoes the combination of ampicillin and azithromycin lower the risk of serious neonatal health problems compared to ampicillin alone?\n\nResearchers will compare two antibiotic regimens:\n\nAmpicillin alone, which is the current standard care Ampicillin with azithromycin, a broader regimen that may better prevent infections and prolong pregnancy\n\nParticipants will:\n\nReceive one of the two antibiotic treatments during hospitalization. Be monitored until delivery for signs of infection and labor\n\nAll participants will stay in the hospital until delivery. The study also looks at how the antibiotic choice may affect the time between membrane rupture and delivery, maternal infections, and the need for neonatal intensive care.",[63,64,28,65,66,67],"Pregnancy Complications, Infectious","Premature Birth","Antibiotic Prophylaxis","Latency Period","Prematurity","2025-12-10",{"date":70,"type":40},"2025-12-18",{"date":72,"type":40},"2025-09-10",{"date":74,"type":20},"2029-07-31",{"name":76,"class":77},"Sheba Medical Center","OTHER_GOV"]